Association between metformin use and mortality in patients with prostate cancer: Explained by confounding by indication?

Journal of Clinical Oncology

Volumn 32, Issue 7, 2014, Pages 701-

  Zanders, Marjolein M J ^a   Vissers, Pauline A J ^a,b   Van De Poll Franse, Lonneke V ^a,b  

^a Eindhoven Cancer Registry   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CANCER DIAGNOSIS; CANCER MORTALITY; COHORT ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; HUMAN; LETTER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STUDY DESIGN; MALE; MORTALITY; NOTE; PROSTATE TUMOR;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PROSTATIC NEOPLASMS;

EID: 84898794513     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.5161     Document Type: Letter

References (3)

1. Margel D, Urbach DR, Lipscombe LL, et al: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069-3075, 2013
2. Suissa S, Azoulay L: Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 35:2665-2673, 2012
3. Colhoun HM, Livingstone SJ, Looker HC, et al: Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929-2937, 2012